Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Molina Healthcare CEO Joseph Zubretsky downplayed GOP proposals to slash spending on Medicaid, which accounts for about 80% ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...